Cargando…
New Points of Departure for More Global Influenza Vaccine Use
Each year, influenza causes a significant acute respiratory disease burden. In addition, influenza pandemics periodically occur. Annual vaccination is the best tool for influenza prevention, but its effectiveness can vary from year to year. The narrow specificity of conventional vaccines and the dru...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563509/ https://www.ncbi.nlm.nih.gov/pubmed/32718042 http://dx.doi.org/10.3390/vaccines8030410 |
_version_ | 1783595505527291904 |
---|---|
author | Kiseleva, Irina |
author_facet | Kiseleva, Irina |
author_sort | Kiseleva, Irina |
collection | PubMed |
description | Each year, influenza causes a significant acute respiratory disease burden. In addition, influenza pandemics periodically occur. Annual vaccination is the best tool for influenza prevention, but its effectiveness can vary from year to year. The narrow specificity of conventional vaccines and the drug resistance of currently circulating viruses reduce the effectiveness of prophylaxis and treatment and require the development of new broad-spectrum preparations. Furthermore, the challenge of creating a highly effective universal influenza vaccine takes on renewed intensity in the face of the COVID-19 pandemic. |
format | Online Article Text |
id | pubmed-7563509 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75635092020-10-27 New Points of Departure for More Global Influenza Vaccine Use Kiseleva, Irina Vaccines (Basel) Editorial Each year, influenza causes a significant acute respiratory disease burden. In addition, influenza pandemics periodically occur. Annual vaccination is the best tool for influenza prevention, but its effectiveness can vary from year to year. The narrow specificity of conventional vaccines and the drug resistance of currently circulating viruses reduce the effectiveness of prophylaxis and treatment and require the development of new broad-spectrum preparations. Furthermore, the challenge of creating a highly effective universal influenza vaccine takes on renewed intensity in the face of the COVID-19 pandemic. MDPI 2020-07-23 /pmc/articles/PMC7563509/ /pubmed/32718042 http://dx.doi.org/10.3390/vaccines8030410 Text en © 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Editorial Kiseleva, Irina New Points of Departure for More Global Influenza Vaccine Use |
title | New Points of Departure for More Global Influenza Vaccine Use |
title_full | New Points of Departure for More Global Influenza Vaccine Use |
title_fullStr | New Points of Departure for More Global Influenza Vaccine Use |
title_full_unstemmed | New Points of Departure for More Global Influenza Vaccine Use |
title_short | New Points of Departure for More Global Influenza Vaccine Use |
title_sort | new points of departure for more global influenza vaccine use |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563509/ https://www.ncbi.nlm.nih.gov/pubmed/32718042 http://dx.doi.org/10.3390/vaccines8030410 |
work_keys_str_mv | AT kiselevairina newpointsofdepartureformoreglobalinfluenzavaccineuse |